%0 Journal Article
%A Rosiñol, Laura
%A Oriol, Albert
%A Rios, Rafael
%A Sureda, Anna
%A Blanchard, María Jesús
%A Hernández, Miguel Teodoro
%A Martínez-Martínez, Rafael
%A Moraleda, Jose M
%A Jarque, Isidro
%A Bargay, Juan
%A Gironella, Mercedes
%A de Arriba, Felipe
%A Palomera, Luis
%A González-Montes, Yolanda
%A Martí, Josep M
%A Krsnik, Isabel
%A Arguiñano, Jose M
%A González, Maria Esther
%A González, Ana Pilar
%A Casado, Luis Felipe
%A López-Anglada, Lucia
%A Paiva, Bruno
%A Mateos, Maria-Victoria
%A San Miguel, Jesus F
%A Lahuerta, Juan-José
%A Bladé, Joan
%T Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
%D 2019
%U http://hdl.handle.net/10668/14471
%X Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients aged ≤65 years with NDMM, is evaluating bortezomib (subcutaneous) + lenalidomide + dexamethasone (VRD) for 6 cycles followed by autologous stem cell transplant (ASCT) conditioned with IV busulfan + melphalan vs melphalan and posttransplant consolidation with 2 cycles of VRD. We present grouped response analysis of induction, transplant, and consolidation. Responses deepened over time; in patients who initiated cycle 6 of induction (n = 426), the rates of a very good partial response or better were 55.6% by cycle 3, 63.8% by cycle 4, 68.3% by cycle 5, and 70.4% after induction. The complete response rate of 33.4% after induction in the intent-to-treat (ITT) population, which was similar in the 92 patients with high-risk cytogenetics (34.8%), also deepened with further treatment (44.1% after ASCT and 50.2% after consolidation). Rates of undetectable minimal residual disease (median 3 × 10-6 sensitivity) in the ITT population also increased from induction (28.8%) to transplant (42.1%) and consolidation (45.2%). The most common grade ≥3 treatment-emergent adverse events during induction were neutropenia (12.9%) and infection (9.2%). Grade ≥2 peripheral neuropathy (grouped term) during induction was 17.0%, with a low frequency of grade 3 (3.7%) and grade 4 (0.2%) events. VRD is an effective and well-tolerated regimen for induction in NDMM with deepening response throughout induction and over the course of treatment. This trial was registered at www.clinicaltrials.gov as #NCT01916252 and EudraCT as #2012-005683-10.
%~